PD-062 Quantum dots for lung cancer biomarkers panels

Lung Cancer ◽  
2005 ◽  
Vol 49 ◽  
pp. S84 ◽  
Author(s):  
T. Zhukov ◽  
M. Dubiec ◽  
P. Zhukov ◽  
N. Korsunska ◽  
S. Ostapenko ◽  
...  
Talanta ◽  
2016 ◽  
Vol 156-157 ◽  
pp. 48-54 ◽  
Author(s):  
Simin Wu ◽  
Lifen Liu ◽  
Gong Li ◽  
Fengxiang Jing ◽  
Hongju Mao ◽  
...  

The Analyst ◽  
2011 ◽  
Vol 136 (7) ◽  
pp. 1399 ◽  
Author(s):  
Huan Li ◽  
Zhijuan Cao ◽  
Yuhao Zhang ◽  
Choiwan Lau ◽  
Jianzhong Lu

2016 ◽  
Vol 80 ◽  
pp. 300-306 ◽  
Author(s):  
Lifen Liu ◽  
Simin Wu ◽  
Fengxiang Jing ◽  
Hongbo Zhou ◽  
Chunping Jia ◽  
...  

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Brett C. Bade ◽  
Geliang Gan ◽  
Fangyong Li ◽  
Lingeng Lu ◽  
Lynn Tanoue ◽  
...  

Abstract Background Lung cancer survivors need more options to improve quality of life (QoL). It is unclear to what extent patients with advanced stage disease are willing to participate in home-based physical activity (PA) and if these interventions improve QoL. The goal of our study was to determine interest in participating in our 3-month home-based walking regimen in patients with advanced stage lung cancer. We used a randomized design to evaluate for potential benefit in PA and patient-reported outcomes. Methods We performed an open-label, 1:1 randomized trial in 40 patients with stage III/IV non-small cell lung cancer (NSCLC) evaluating enrollment rate, PA, QoL, dyspnea, depression, and biomarkers. Compared to usual care (UC), the intervention group (IG) received an accelerometer, in-person teaching session, and gain-framed text messages for 12 weeks. Results We enrolled 56% (40/71) of eligible patients. Participants were on average 65 years and enrolled 1.9 years from diagnosis. Most patients were women (75%), and receiving treatment (85%) for stage IV (73%) adenocarcinoma (83%). A minority of patients were employed part-time or full time (38%). Both groups reported low baseline PA (IG mean 37 (Standard deviation (SD) 46) vs UC 59 (SD 56) minutes/week; p = 0.25). The IG increased PA more than UC (mean change IG + 123 (SD 212) vs UC + 35 (SD 103) minutes/week; p = 0.051)). Step count in the IG was not statistically different between baseline (4707 step/day), week 6 (5605; p = 0.16), and week 12 (4606 steps/day; p = 0.87). The intervention improved EORTC role functioning domain (17 points; p = 0.022) with borderline improvement in dyspnea (− 13 points; p = 0.051) compared to UC. In patients with two blood samples (25%), we observed a significant increase in soluble PD-1 (219.8 (SD 54.5) pg/mL; p < 0.001). Conclusions Our pilot trial using a 3-month, home-based, mobile health intervention enrolled over half of eligible patients with stage III and IV NSCLC. The intervention increased PA, and may improve several aspects of QoL. We also identified potential biomarker changes relevant to lung cancer biology. Future research should use a larger sample to examine the effect of exercise on cancer biomarkers, which may mediate the association between PA and QoL. Clinical trial registration Clinicaltrials.gov (NCT03352245).


2017 ◽  
Vol 33 (1) ◽  
pp. 3-9 ◽  
Author(s):  
Yan Song ◽  
Xiuli Yu ◽  
Zongmei Zang ◽  
Guijuan Zhao

For both lung cancer patients and clinical physicians, tumor biomarkers for more efficient early diagnosis and prediction of prognosis are always wanted. Biomarkers in circulating serum, including microRNAs (miRNAs) and extracellular vesicles, hold the greatest possibilities to partially substitute for tissue biopsy. In this systematic review, studies on circulating or tissue miRNAs and extracellular vesicles as potential biomarkers for lung cancer patients were reviewed and are discussed. Furthermore, the target genes of the miRNAs indicated were identified through the miRTarBase, while the relevant biological processes and pathways of miRNAs in lung cancer were analyzed through MiRNA Enrichment Analysis and Annotation (MiEAA). In conclusion, circulating or tissue miRNAs and extracellular vesicles provide us with a window to explore strategies for diagnosing and assessing prognosis and treatment in lung cancer patients.


2016 ◽  
Vol 8 (34) ◽  
pp. 22442-22450 ◽  
Author(s):  
Xiaoli Cai ◽  
Yanan Luo ◽  
Weiying Zhang ◽  
Dan Du ◽  
Yuehe Lin

2013 ◽  
Vol 46 (10-11) ◽  
pp. 918-925 ◽  
Author(s):  
Ivan Vannini ◽  
Francesca Fanini ◽  
Muller Fabbri

2010 ◽  
Vol 397 (8) ◽  
pp. 3213-3224 ◽  
Author(s):  
Megan K. Wagner ◽  
Feng Li ◽  
Jingjing Li ◽  
Xing-Fang Li ◽  
X. Chris Le

Sign in / Sign up

Export Citation Format

Share Document